These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 37308914)

  • 1. Lenvatinib with or without stereotactic body radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis: a retrospective study.
    Ji X; Xu Z; Sun J; Li W; Duan X; Wang Q
    Radiat Oncol; 2023 Jun; 18(1):101. PubMed ID: 37308914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of stereotactic body radiotherapy with and without lenvatinib for advanced hepatocellular carcinoma: a propensity score analysis.
    Wang Q; Ji X; Sun J; Li W; Duan X; Zhang A
    J Cancer Res Clin Oncol; 2023 Aug; 149(10):7441-7452. PubMed ID: 36952005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereotactic body radiotherapy versus lenvatinib for hepatocellular carcinoma with portal vein tumor thrombosis: a propensity matching score analysis.
    Ji X; Zhang A; Duan X; Wang Q
    Radiat Oncol; 2024 Oct; 19(1):143. PubMed ID: 39394613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of transarterial chemoembolization combined with lenvatinib, programmed death-1 inhibitor, and iodine-125 seed brachytherapy for hepatocellular carcinoma with portal vein tumor thrombosis.
    Lin LW; Yan LY; Ke K; Yang WZ; Lin JQ; Huang N
    Brachytherapy; 2023; 22(6):858-871. PubMed ID: 37574351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation and efficacy of TACE combined with lenvatinib plus PD-1 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on immunological features.
    Zou X; Xu Q; You R; Yin G
    Cancer Med; 2023 May; 12(10):11315-11333. PubMed ID: 36951443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereotactic body radiotherapy based treatment for hepatocellular carcinoma with extensive portal vein tumor thrombosis.
    Shui Y; Yu W; Ren X; Guo Y; Xu J; Ma T; Zhang B; Wu J; Li Q; Hu Q; Shen L; Bai X; Liang T; Wei Q
    Radiat Oncol; 2018 Sep; 13(1):188. PubMed ID: 30253783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.
    Ding X; Sun W; Li W; Shen Y; Guo X; Teng Y; Liu X; Zheng L; Li W; Chen J
    Cancer; 2021 Oct; 127(20):3782-3793. PubMed ID: 34237154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereotactic body radiotherapy plus transcatheter arterial chemoembolization for inoperable hepatocellular carcinoma patients with portal vein tumour thrombus: A meta-analysis.
    Zhang XF; Lai L; Zhou H; Mo YJ; Lu XQ; Liu M; Lu YX; Hou EC
    PLoS One; 2022; 17(5):e0268779. PubMed ID: 35594278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis.
    Fu Y; Peng W; Zhang W; Yang Z; Hu Z; Pang Y; Hu D; Chen J; Wang J; Zhou Z; Xu L; Chen M; Zhang Y
    J Gastroenterol; 2023 Apr; 58(4):413-424. PubMed ID: 36894804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereotactic body radiotherapy versus intensity-modulated radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis.
    Li LQ; Zhou Y; Huang Y; Liang P; Liang SX; Su TS
    Hepatol Int; 2021 Jun; 15(3):630-641. PubMed ID: 33818714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stereotactic Body Radiotherapy Combined With Lenvatinib With or Without PD-1 Inhibitors as Initial Treatment for Unresectable Hepatocellular Carcinoma.
    Wang Q; Ji X; Sun J; Zhang A; Jia J; Zhang T; Li W; Duan X
    Int J Radiat Oncol Biol Phys; 2024 Dec; 120(5):1363-1376. PubMed ID: 38583495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating the Benefits of TACE Combined with Lenvatinib Plus PD-1 Inhibitor for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.
    Zou X; Xu Q; You R; Yin G
    Adv Ther; 2023 Apr; 40(4):1686-1704. PubMed ID: 36805422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of anti-PD-1 monotherapy
    Liu Q; Li R; Li L; Wang G; Ji S; Zheng X; Jia X; Tao H; Hu Y
    Ther Adv Med Oncol; 2023; 15():17588359231206274. PubMed ID: 37885459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter prospective study of TACE combined with lenvatinib and camrelizumab for hepatocellular carcinoma with portal vein tumor thrombus.
    Li X; Ding X; Liu M; Wang J; Sun W; Teng Y; Xu Y; Wu H; Li W; Zhou L; Chen J
    Cancer Med; 2023 Aug; 12(16):16805-16814. PubMed ID: 37387602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Efficacy of Liver-Directed Radiotherapy in Combination With Lenvatinib for Hepatocelluar Carcinoma With Macroscopic Tumor Thrombosis.
    Yu JI; Kang W; Yoo GS; Goh MJ; Sinn DH; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW; Hong JY; Lim HY; Park B; Park HC
    Front Oncol; 2022; 12():888755. PubMed ID: 35646674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Portal vein tumour thrombosis radiotherapy improves the treatment outcomes of immunotherapy plus bevacizumab in hepatocellular carcinoma: a multicentre real-world analysis with propensity score matching.
    Tang C; He Q; Feng J; Liao Z; Peng Y; Gao J
    Front Immunol; 2023; 14():1254158. PubMed ID: 37928530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis.
    Hur MH; Cho Y; Kim DY; Lee JS; Kim GM; Kim HC; Sinn DH; Hyun D; Lee HA; Seo YS; Lee IJ; Park JW; Kim YJ
    Clin Mol Hepatol; 2023 Jul; 29(3):763-778. PubMed ID: 37254488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and safety of vascular intervention plus lenvatinib versus vascular intervention alone for hepatocellular carcinoma patients with portal vein tumor thrombus: a retrospective comparative study.
    Tang S; Gao Y; Yan X; Zhi W; Han Y
    Front Oncol; 2024; 14():1431069. PubMed ID: 39035736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of stereotactic body radiation therapy with and without sorafenib as treatment for hepatocellular carcinoma with portal vein tumor thrombosis.
    Que J; Wu HC; Lin CH; Huang CI; Li LC; Ho CH
    Medicine (Baltimore); 2020 Mar; 99(13):e19660. PubMed ID: 32221093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of transarterial chemoembolization-lenvatinib sequential therapy for the treatment of hepatocellular carcinoma with portal vein tumor thrombus: a retrospective study.
    Chen R; Li Y; Song K; Li L; Shen C; Ma P; Wang Z
    J Gastrointest Oncol; 2022 Apr; 13(2):780-786. PubMed ID: 35557575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.